- Home
- SONM vs AYTU Comparison
SONM vs AYTU Comparison
Compare SONM & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SONM | AYTU |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5M | 25.7M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SONM | AYTU |
|---|---|---|
| Price | $3.14 | $2.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 19.4K | ★ 41.1K |
| Earning Date | 04-06-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $58,298,000.00 | $27,632,080.00 |
| Revenue This Year | $127.68 | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.52 | $0.95 |
| 52 Week High | $12.30 | $3.07 |
Technical Indicators
Market Signals| Indicator | SONM | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 30.38 | 57.06 |
| Support Level | $0.66 | $2.14 |
| Resistance Level | $7.08 | $2.66 |
| Average True Range (ATR) | 0.42 | 0.11 |
| MACD | -0.14 | 0.00 |
| Stochastic Oscillator | 3.31 | 70.83 |
Price Performance
Historical ComparisonAbout SONM Sonim Technologies Inc.
DNA X Inc operates a digital asset management platform.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.